Literature DB >> 2016229

Clinical effects of methylphenidate and thioridazine in intellectually subaverage children.

M G Aman1, R E Marks, S H Turbott, C P Wilsher, S N Merry.   

Abstract

Thirty children with subaverage IQs and psychiatric diagnoses of attention deficit disorder and/or or conduct disorder took part in a double-blind study of placebo, methylphenidate, and thioridazine, which were given for 3 weeks each. The results showed a consistent and highly significant effect of methylphenidate in reducing teacher ratings of problem behavior. Parent ratings showed no behavioral effects for the group as a whole. An attentional model of stimulant drug response was used to divide subjects according to a cognitive maturity domain presumed to reflect selective attention. When divided according to breadth of attention, mental age, and IQ level, higher functioning subjects were found to show a generally favorable response to methylphenidate on both teacher and parent rating scales, whereas children of low functional level typically showed an adverse or indifferent response. The present data suggest that mental age and IQ may be important determinants of drug response; below a given level, there was a greatly reduced likelihood of responding positively. Clinical response to thioridazine was substantially less than the response to methylphenidate, with significant improvements confined to conduct and hyperactivity problems on teacher ratings.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2016229     DOI: 10.1097/00004583-199103000-00013

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  16 in total

Review 1.  Typical neuroleptics in child and adolescent psychiatry.

Authors:  C Gillberg
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 2.  Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 3.  Management of psychopharmacologic agents in children and adolescents.

Authors:  G A Carlson; L Ranade; A Qadir
Journal:  Psychiatr Q       Date:  1992

4.  Long-term follow-up of children with mental retardation/borderline intellectual functioning and ADHD.

Authors:  B L Handen; J Janosky; S McAuliffe
Journal:  J Abnorm Child Psychol       Date:  1997-08

5.  Separate and combined effects of methylphenidate and a behavioral intervention on disruptive behavior in children with mental retardation.

Authors:  N J Blum; J E Mauk; J J McComas; F C Mace
Journal:  J Appl Behav Anal       Date:  1996

6.  Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Authors:  Deborah A Pearson; Cynthia W Santos; Michael G Aman; L Eugene Arnold; David M Lane; Katherine A Loveland; Rosleen Mansour; Anthony R Ward; Charles D Casat; Susan Jerger; Russell J Schachar; Oscar G Bukstein; Lynne A Cleveland
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-07-09       Impact factor: 2.576

Review 7.  Medication treatment in subjects with autistic spectrum disorders.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 8.  Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder.

Authors:  M Cyr; C S Brown
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

9.  Central Stimulant Treatment of Childhood Attention Deficit Hyperactivity Disorder : Issues and Recommendations from a US Perspective.

Authors:  D J Safer
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 10.  Risks and benefits of drugs used in the management of the hyperactive child.

Authors:  A M Fox; M J Rieder
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.